Search Results
Your search for Matthew Stenger matches 7475 pages
Showing 651 - 700Primary Cancer and Noncancer Mortality Among Long-Term Survivors of Solid Tumors
In a study reported in JAMA Network Open, KC et al identified factors involved with primary cancer mortality vs noncancer mortality among long-term survivors of breast, prostate, and colorectal cancers. Study Details The study included data on 627,702 patients in the Surveillance, Epidemiology,...
Niraparib Maintenance in Newly Diagnosed Advanced Ovarian Cancer
In a Chinese phase III study reported in JAMA Oncology, Li et al found that niraparib maintenance therapy given with an individualized starting dose improved progression-free survival vs placebo in newly diagnosed patients with advanced ovarian cancer. Study Details In the double-blind multicenter...
Polygenic Risk Score and Chemotherapy-Related Subsequent Malignant Neoplasms in Childhood Cancer Survivors
In a study reported in the Journal of Clinical Oncology, Im et al found that a polygenic risk score (PRS) may be useful in stratifying risk for subsequent malignant neoplasms among nonirradiated survivors of childhood cancer according to chemotherapy received. Study Details The study involved...
Integrated Clinical-Molecular Classification of Colorectal Liver Metastases
In a study reported in JAMA Oncology, Katipally et al found that an integrated clinical-molecular classification of colorectal cancer metastases to the liver distinguished risk groups for survival outcomes. Study Details The investigators had previously defined three biologically distinct molecular ...
Atezolizumab, Vemurafenib, and Cobimetinib in Patients With BRAF V600–Mutated Melanoma and CNS Metastases
A revised report of findings from the phase II TRICOTEL study of atezolizumab, vemurafenib, and cobimetinib in patients with melanoma and central nervous system (CNS) metastases was published in The Lancet Oncology by Reinhard Dummer, MD, and colleagues. The first version of trial findings,...
Addition of Nivolumab to SABR in Early-Stage or Isolated Lung Parenchymal Recurrent NSCLC
In the phase II I-SABR trial reported in The Lancet, Chang et al found that the addition of nivolumab to stereotactic ablative radiotherapy (SABR) improved event-free survival in patients with previously untreated stage I or II or isolated parenchymal recurrent node-negative non–small cell lung...
Glofitamab-gxbm for Select Relapsed or Refractory Large B-Cell Lymphomas
On June 15, 2023, the bispecific CD20-directed CD3 T-cell engager glofitamab-gxbm was granted accelerated approval for relapsed or refractory diffuse large B-cell lymphoma (DLBCL)–not otherwise specified or large B-cell lymphoma (LBCL) arising from follicular lymphoma after at least two lines of...
Stereotactic Radiosurgery Before Resection of Brain Metastases From Solid Tumors
In a study reported in JAMA Oncology, Prabhu et al identified outcomes and associated risk factors among patients receiving stereotactic radiosurgery (SRS) prior to resection of brain metastases from solid tumors. Study Details The study involved data from an international multicenter cohort...
Intervention to Increase Uptake of Tobacco Use Treatment for Patients With Cancer Who Smoke
In a study reported in the Journal of Clinical Oncology, Jenssen et al found that electronic health record (EHR)-based nudges to clinicians significantly increased the uptake of tobacco use treatment in patients with cancer who were current smokers. Study Details In the trial—performed across 11...
Olaparib and Temozolomide in Advanced Uterine Leiomyosarcoma
In a phase II trial (NCI Protocol 10250) reported in the Journal of Clinical Oncology, Ingham et al found that the combination of olaparib and temozolomide showed activity in previously treated patients with advanced uterine leiomyosarcoma. Study Details In the multicenter trial, 22 evaluable...
Addition of SBRT to Immunotherapy in Advanced Solid Tumors
In the Belgian phase II CHEERS trial reported in JAMA Oncology, Spaas et al evaluated the addition of stereotactic body radiotherapy (SBRT) to anti–PD-1/PD-L1 immune checkpoint inhibitor therapy, with SBRT directed to a maximum of three lesions, in patients with advanced solid tumors. The...
Overall Survival With Axicabtagene Ciloleucel in Large B-Cell Lymphoma: Results From ZUMA-7
As reported in The New England Journal of Medicine by Jason R. Westin, MD, and colleagues, the overall survival analysis from the phase III ZUMA-7 trial showed significant benefit with axicabtagene ciloleucel vs standard care in patients with early relapsed or refractory large B-cell lymphoma. The...
Individual Patient Meta-analysis of Neoadjuvant Chemotherapy and Chemoradiotherapy for Esophageal or GEJ Carcinoma
In a meta-analysis reported in the Journal of Clinical Oncology, Faron et al found that neoadjuvant chemotherapy and chemoradiotherapy were associated with better survival vs upfront surgery in patients with thoracic esophageal or gastroesophageal junction (GEJ) carcinoma. Study Details The study...
First-Line Atezolizumab vs Single-Agent Chemotherapy in Patients With Advanced NSCLC Ineligible for Platinum-Based Chemotherapy
In the phase III IPSOS trial reported in The Lancet, Lee et al found that first-line atezolizumab improved overall survival vs single-agent chemotherapy in patients with advanced non–small cell lung cancer (NSCLC) who were ineligible for platinum-based chemotherapy. Study Details In the open-label...
Implementation of Pediatric Early Warning Systems in Resource-Limited Latin American Hospitals
In a study reported in The Lancet Oncology, Agulnik et al found that implementation of pediatric early warning systems resulted in reduced clinical deterioration event mortality among children with cancer in resource-limited hospitals in Latin America. Study Details The Proyecto Escala de...
Dysphagia-Optimized vs Standard IMRT in Newly Diagnosed Patients With Head and Neck Cancer
In the phase III DARS study reported in The Lancet Oncology, Nutting et al found that dysphagia-optimized intensity-modulated radiotherapy (DO-IMRT) was associated with improved patient-reported swallowing function vs standard IMRT in newly diagnosed patients with head and neck cancer. Study...
Incorporation of Gilteritinib Into Induction and Consolidation Chemotherapy and as Maintenance Therapy in Newly Diagnosed Patients With AML
In a phase Ib trial (2215-CL-0103) reported in the Journal of Clinical Oncology, Keith W. Pratz, MD, and colleagues found that incorporation of the FLT3 inhibitor gilteritinib into intensive induction and consolidation chemotherapy and its use as single-agent maintenance therapy were associated...
Activity and Toxicity of Pembrolizumab in Rare Sarcomas
In a French phase II basket trial (AcSé Pembrolizumab) reported in The Lancet Oncology, Jean-Yves Blay, MD, and colleagues investigated the activity and safety of pembrolizumab in patients with rare sarcomas. AcSé Pembrolizumab is an ongoing phase II multitumor study investigating the activity of...
Adjuvant Osimertinib in Resected EGFR-Mutant NSCLC: Overall Survival Analysis of the ADAURA Trial
As reported in The New England Journal of Medicine by Masahiro Tsuboi, MD, and colleagues, the planned final overall survival analysis of the phase III ADAURA trial has shown a significant benefit with osimertinib vs placebo in patients with resected EGFR-mutant non–small cell lung cancer (NSCLC)....
Trends in Receipt of End-of-Life Systemic Treatment for Patients With Cancer
In a U.S. study reported in the Journal of Clinical Oncology, Canavan et al found that White vs Black patients, patients with commercial insurance vs Medicare/Medicaid, and patients treated at community practices vs academic centers were more likely to receive end-of-life systemic therapy for...
Adjuvant Nivolumab vs Observation for Patients With Completely Resected Merkel Cell Carcinoma
As reported in The Lancet by Becker et al, an interim analysis of a European phase II study (ADMEC-O) showed that adjuvant nivolumab was associated with a numeric benefit in disease-free survival vs observation in patients with completely resected Merkel cell carcinoma. Study Details In the...
First-Line Pembrolizumab/Lenvatinib in Advanced Non–Clear Cell Renal Cell Carcinoma
In the phase II KEYNOTE-B61 trial reported in The Lancet Oncology, Laurence Albiges, MD, PhD, and colleagues found that first-line pembrolizumab plus lenvatinib produced durable responses in patients with advanced non–clear cell renal cell carcinoma. As stated by the investigators,...
Regional Nodal Irradiation and Locoregional Recurrence in Patients With Favorable-Risk Node-Positive Breast Cancer
In a secondary analysis from the SWOG S1007 trial reported in JAMA Oncology, Reshma Jagsi, MD, DPhil, and colleagues found low rates of locoregional recurrence irrespective of the use of regional nodal irradiation in patients with favorable-risk, node-positive breast cancer receiving radiation...
Vemurafenib Plus Cobimetinib in Newly Diagnosed Patients With Papillary Craniopharyngiomas
In a small phase II trial reported in The New England Journal of Medicine, Priscilla K. Brastianos, MD, and colleagues found that the BRAF-MEK inhibitor combination of vemurafenib and cobimetinib produced an objective response in almost all patients with newly diagnosed papillary craniopharyngiomas ...
Addition of Atezolizumab to Cabozantinib in Renal Cell Carcinoma Progressing During or After Prior Immune Checkpoint Inhibition
In the phase III CONTACT-03 trial reported in The Lancet, Sumanta Pal, MD, FASCO, and colleagues found that the addition of atezolizumab to cabozantinib did not improve outcomes in patients with renal cell carcinoma whose disease progressed on or after prior immune checkpoint inhibitor treatment....
Lazertinib vs Gefitinib in the First-Line Treatment of EGFR-Mutated Advanced NSCLC
In a phase III trial (LASER301) reported in the Journal of Clinical Oncology, Byoung Chul Cho, MD, PhD, and colleagues found that lazertinib improved progression-free survival vs gefitinib in the first-line treatment of EGFR-mutated advanced non–small cell lung cancer (NSCLC). As stated by the...
Crenigacestat Plus BCMA CAR T-Cell Therapy in Relapsed or Refractory Multiple Myeloma
In a single-institution, phase I, first-in-human trial reported in The Lancet Oncology, Cowan et al found that the combination of the γ-secretase inhibitor (GSI) crenigacestat and B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T-cell therapy was tolerable and produced a high...
Meta-analysis of the Addition of Docetaxel to ADT in Metastatic Hormone-Sensitive Prostate Cancer
In a systematic review and individual patient meta-analysis reported in The Lancet Oncology, Claire L. Vale, PhD, and colleagues in the STOPCAP M1 collaboration identified factors associated and not associated with improved outcomes after the addition of docetaxel to androgen-deprivation therapy...
Use of Zipalertinib in Previously Treated Patients With Advanced NSCLC and EGFR Exon 20 Insertions
In a phase I/IIa study reported in the Journal of Clinical Oncology, Piotrowska et al found that the EGFR tyrosine kinase inhibitor zipalertinib showed activity and an acceptable safety profile in previously treated patients with advanced non–small cell lung cancer (NSCLC) and EGFR exon 20...
Incidence and Outcomes of Severe Hepatopathy in National Wilms Tumor Study Protocols
In an analysis of National Wilms Tumor Study (NWTS) protocols reported in the Journal of Clinical Oncology, Oosterom et al identified the incidence of treatment-related severe hepatopathy in patients with Wilms tumor and described outcomes in these patients. Study Details The study involved data...
Academically Developed BCMA-Directed CAR T-Cell Therapy in Relapsed or Refractory Multiple Myeloma
In an interim analysis of a Spanish pilot trial (CARTBCMA-HCB-01) reported in The Lancet Oncology, Oliver-Caldés et al found that an academically developed B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T-cell therapy, ARI0002h, showed activity in patients with relapsed...
Functional Recovery and Quality of Life in Older Patients Undergoing Colorectal Cancer Surgery
In a study of real-world prospective data—GOSAFE—reported in the Journal of Clinical Oncology, Montroni et al found that the majority of patients aged ≥ 70 years undergoing colorectal cancer surgery showed maintained or improved quality of life and achieved functional recovery during follow-up....
Zanidatamab in HER2-Positive Advanced Biliary Tract Cancer
In the phase IIb HERIZON-BTC-01 trial reported in The Lancet Oncology, James J. Harding, MD, and colleagues found that zanidatamab—a bispecific antibody targeting two distinct HER2 epitopes—showed activity in previously treated patients with HER2-positive advanced biliary tract cancer. Study...
Pirtobrutinib After Covalent BTK Inhibitor Treatment in Relapsed or Refractory CLL/SLL
In the phase I/II BRUIN trial reported in The New England Journal of Medicine, Anthony R. Mato, MD, and colleagues found that the noncovalent (reversible) Bruton’s tyrosine kinase (BTK) inhibitor pirtobrutinib exhibited strong activity in patients with relapsed or refractory chronic lymphocytic...
Intraoperative MRI-Guided vs Aminolevulinic Acid–Guided Resection in Newly Diagnosed Patients With Glioblastoma
In a German trial reported in the Journal of Clinical Oncology, Roder et al found that intraoperative magnetic resonance imaging (MRI)-guided surgery did not improve the rate of complete resection vs fluorescence-guided surgery with aminolevulinic acid (5-ALA) in newly diagnosed patients with...
Prediction of Lung Cancer Mortality With Blood-Based Biomarker Panel and PLCO Risk Model
In a study reported in the Journal of Clinical Oncology, Irajizad et al found that use of a blood-based four-marker protein panel (4MP)—together with the Prostate, Lung, Colorectal, and Ovarian (PLCOm2012) lung cancer risk model—was capable of identifying patients at high risk of lung cancer...
Germline Variants in Colorectal Cancer Susceptibility Genes by Race/Ethnicity in Patients With Early-Onset Colorectal Cancer
In a study reported in the Journal of Clinical Oncology, Seagle et al identified the prevalence of germline colorectal cancer susceptibility gene variants according to race and ethnicity among patients with early-onset colorectal cancer. Study Details The study involved patients aged 15 to 49 years ...
Prevalence of Prior Cancer Among Patients With Newly Diagnosed Cancer
In an analysis of Surveillance, Epidemiology, and End Results (SEER) data reported in a research letter in JAMA Oncology, Caitlin C. Murphy, PhD, MPH, and colleagues found that a substantial proportion of patients diagnosed with an incident cancer in 2019 had a history of prior cancer diagnosis....
Second-Line Trastuzumab, Ramucirumab, and Paclitaxel in Previously Treated Patients With HER2-Positive Advanced Gastric or Gastroesophageal Junction Cancer
In a Korean phase Ib/II trial reported in the Journal of Clinical Oncology, Kim et al found that trastuzumab combined with ramucirumab and paclitaxel showed activity in the second-line treatment of patients with HER2-positive advanced gastric or gastroesophageal junction cancer whose disease...
Olaparib With Abiraterone and Prednisone or Prednisolone for BRCA-Mutated, Metastatic Castration-Resistant Prostate Cancer
On May 31, 2023, the PARP inhibitor olaparib was approved by the U.S. Food and Drug Administration (FDA) with abiraterone and prednisone or prednisolone for the treatment of BRCA-mutated metastatic castration-resistant prostate cancer, as determined by an FDA-approved companion diagnostic test.1...
Epcoritamab-bysp in Treatment of Relapsed or Refractory B-Cell Lymphomas
On May 19, 2023, epcoritamab-bysp was granted accelerated approval by the U.S. Food and Drug Administration for treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL)–not otherwise specified, including DLBCL arising from indolent lymphoma, and high-grade B-cell lymphoma after two ...
Addition of Tislelizumab to Chemotherapy Improves Survival in Treatment of Metastatic Esophageal Squamous Cell Carcinoma
As reported in The Lancet Oncology by Jianming Xu, MD, of Fifth Medical Center, Chinese PLA General Hospital, Beijing, corresponding author Harry H. Yoon, MD, of the Department of Oncology, Mayo Clinic, Rochester, and colleagues, an interim analysis of the phase III RATIONALE-306 trial has shown...
Intracranial Activity of Adagrasib in Patients With KRAS G12C–Mutated NSCLC and Untreated CNS Metastases
In an analysis reported in the Journal of Clinical Oncology, Negrao et al identified outcomes in the KRYSTAL-1 trial among patients with advanced KRAS G12C–mutated non–small cell lung cancer (NSCLC) who had untreated central nervous system (CNS) metastases at baseline and were treated with...
Cancer Mortality Trends Among U.S. Hispanic Populations From 1999 to 2020
In a cross-sectional study reported in JAMA Oncology, Pompa et al found that overall cancer-specific mortality among U.S. Hispanic populations decreased between 1999 and 2020; however, mortality from some cancer types increased in the populations over this period. Study Details The study used data...
Association of Alcohol Intake With Risk of Early-Onset Colorectal Cancer
In a Korean study reported in the Journal of Clinical Oncology, Jin et al found that increased alcohol intake may be associated with an increased risk of early-onset colorectal cancer. Study Details The study involved data from 5,666,576 individuals aged 20 to 49 years from the Korean National...
First-Line FOLFOXIRI Plus Cetuximab or Bevacizumab in BRAF V600E–Mutant Metastatic Colorectal Cancer
In the German phase II FIRE-4.5 trial reported in the Journal of Clinical Oncology, Stintzing et al found that the addition of cetuximab vs bevacizumab to FOLFOXIRI (fluorouracil, leucovorin, oxaliplatin, and irinotecan) did not improve objective response rate in the first-line treatment of...
Addition of Neoadjuvant Nivolumab to Platinum-Based Chemotherapy in Stage III NSCLC
In the Spanish phase II NADIM II trial reported in The New England Journal of Medicine, Mariano Provencio, MD, PhD, and colleagues found that the addition of nivolumab to platinum-based chemotherapy improved pathologic complete response (pCR) rates among patients with resectable stage IIIA or IIIB...
Addition of Relacorilant to Nab-paclitaxel in Recurrent, Platinum-Resistant Ovarian Cancer
In a phase II trial reported in the Journal of Clinical Oncology, Nicoletta Colombo, MD, and colleagues found that the selective glucocorticoid receptor modulator relacorilant (given on an intermittent schedule) plus nab-paclitaxel showed benefits vs nab-paclitaxel alone in patients with recurrent, ...
First-Line Systemic Treatment Strategies for Initially Unresectable Colorectal Cancer Liver Metastases
In the Dutch Colorectal Cancer Group phase III CAIRO5 study reported in The Lancet Oncology, Bond et al investigated first-line systemic treatment strategies in patients with initially unresectable colorectal cancer liver metastases. The researchers found that FOLFOXIRI (leucovorin, fluorouracil,...
First-Line Enfortumab Vedotin Plus Pembrolizumab in Cisplatin-Ineligible Patients With Locally Advanced or Metastatic Urothelial Cancer
As reported in the Journal of Clinical Oncology by O’Donnell et al, findings in a cohort of the phase Ib/II EV-103/KEYNOTE-869 study showed durable responses with first-line enfortumab vedotin-ejfv plus pembrolizumab in cisplatin-ineligible patients with locally advanced or metastatic urothelial...
